EUVIMEDEUVIMED entdecken
Fallbericht

Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report

Dana Reynolds, Lauren M Mitteer, Winifred Sigal, Linda Boyajian, Heather McKnight, Tricia Bhatti, Lisa States, Susan Becker, N Scott Adzick, Katherine Lord, Diva D De Leon

Hormone Research in Paediatrics · 2024

DOI: 10.1159/000531251 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Dana Reynolds und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Glucagon, Hyperinsulinism, Hypoglycemia. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hyperinsulinemic hypoglycemia is the most common cause of persistent hypoglycemia in children and adults. In adolescents and adults, hyperinsulinemic hypoglycemia is most frequently caused by an insulin-producing tumor. Case Presentation: A 17-year-old, previously healthy male presented with recurrent and severe episodes of hypoglycemia. Diagnostic evaluation was consistent with hyperinsulinemic hypoglycemia, and an insulinoma was suspected. Multiple imaging studies and surgical exploration failed to identify a lesion. Over the course of months, the patient was found to be refractory to conventional medical interventions.

Conclusion

Upon approval from the US Food and Drug Administration and the Institutional Review Board, the patient was treated with dasiglucagon, a novel soluble glucagon analog, under a single-patient Investigational New Drug. The patient has tolerated the medication and has been able to achieve appropriate glycemic control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucagonHyperinsulinismHypoglycemiaAdolescentHumansMaleInsulinomaPancreatic Neoplasms

Stichwörter der Autor:innen

Case reportGlucagonHypoglycemiaInsulinPancreas

Substanzen

dasiglucagonGlucagon

Autor:innen und Institutionen

  • Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, mitteerl@chop.edu.
  • Congenital Hyperinsulinism Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, mitteerl@chop.edu.
  • Congenital Hyperinsulinism Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Radiology, Children's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Zitieren

APA

Reynolds, D., Mitteer, L. M., Sigal, W., Boyajian, L., McKnight, H., Bhatti, T., States, L., Becker, S., Adzick, N. S., Lord, K., & De Leon, D. D. (2024). Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report. Hormone Research in Paediatrics. https://doi.org/10.1159/000531251

Vancouver

Reynolds D, Mitteer LM, Sigal W, Boyajian L, McKnight H, Bhatti T, et al. Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report. Hormone Research in Paediatrics. 2024. doi:10.1159/000531251

BibTeX
@article{Reynolds2024,
  author = {Reynolds, Dana and Mitteer, Lauren M and Sigal, Winifred and Boyajian, Linda and McKnight, Heather and Bhatti, Tricia and States, Lisa and Becker, Susan and Adzick, N Scott and Lord, Katherine and De Leon, Diva D},
  title = {Novel Use of Dasiglucagon, a Soluble Glucagon Analog, for the Treatment of Hyperinsulinemic Hypoglycemia Secondary to Suspected Insulinoma: A Case Report},
  journal = {Hormone Research in Paediatrics},
  year = {2024},
  doi = {10.1159/000531251}
}
Kostenlos starten →